Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® taking place Nov. 12-15, 2021.
The first abstract provides clinical data from the Company’s Phase 1 trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD).
Session: Metabolic and Genetic Disease: Hemochromatosis, Wilson Disease, α-1 Antitrypsin Deficiency
Poster Title: Belcesiran Was Well-Tolerated and Reduced Serum AAT Levels in Healthy Volunteers (Phase 1 Interim Results)
Poster #: 27962
Abstract #: 1549
An additional abstract provides results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346 (RO7445482), an investigational GalXC RNAi therapeutic that Dicerna is developing in collaboration with Roche for the treatment of chronic hepatitis B virus (HBV) infection.
Session: Hepatitis B: Therapeutics: New Agents
Poster Title: The Pharmacokinetic and Safety Profiles of RO7445482 siRNA Are Similar Between Asian and Non-Asian Healthy Volunteers and Chronic Hepatitis B Patients in a Phase 1 Study
Poster #: 28577
Abstract #: 850
Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.